筋層非浸潤性膀胱癌に対する再発予防目的Mitomycin C膀胱内注入療法の検討

HANDLE Web Site オープンアクセス

書誌事項

タイトル別名
  • Efficacy of Prophylactic Intravesical Mitomycin C in Patients with Non-Muscle-Invasive Bladder Cancer
  • キンソウ ヒシンジュンセイ ボウコウガン ニ タイスル サイハツ ヨボウ モクテキ Mitomycin C ボウコウ ナイ チュウニュウ リョウホウ ノ ケントウ

この論文をさがす

抄録

Intravesical chemotherapy is beneficial for patients with non-muscle-invasive bladder cancer (NMIBC), but optimal drug and regimen selection can be controversial. Mitomycin C (MMC) is commonly used as adjuvant treatment for NMIBC. We retrospectively evaluated the outcomes of 73 patients with NMIBC who were treated with weekly doses of low-dose MMC (20 mg ; n=28 ; 38.4%) orhigh-dose MMC (40 mg ; n=45 ; 61.6%) for6 weeks each, at ourhospital between 2001 and 2010. Treatment outcomes were examined by Kaplan‒Meier analysis with log-rank tests. Patients in the high-dose group showed greater recurrent-free survival (61.3%) at 2 years than did patients in the low-dose group (32.6%) (P<0.05). We also found that a single early dose of pirarubicin following transurethral resection of bladder tumor improved MMC efficacy in the high-dose group. The high-dose group had a somewhat higher incidence of dysuria, urinary frequency and drug eruption, but the difference was not significant.

収録刊行物

  • 泌尿器科紀要

    泌尿器科紀要 60 (8), 375-379, 2014-08

    泌尿器科紀要刊行会

キーワード

詳細情報 詳細情報について

問題の指摘

ページトップへ